Nasdaq Trading Volume Surges 170.86% to Rank 94th Despite Stock Price Dip

On May 14, 2025, Nasdaq's trading volume reached 8.99 billion, marking a significant 170.86% increase from the previous day. This surge placed Nasdaq at the 94th position in terms of trading volume among all stocks traded that day. However, Nasdaq's stock price experienced a slight decline of 0.63%.

Humacyte, Inc., a biotechnology company listed on Nasdaq, reported its first-quarter 2025 financial results. The company's revenue for the quarter was $517,000, with $147,000 coming from the initial U.S. commercial launch of Symvess, an acellular tissue engineered vessel. The remaining $370,000 was generated from a research collaboration with a large medical technology company. Humacyte also announced that it had commenced the commercial launch of Symvess in late February 2025, with the first commercial shipments made to three Level 1 trauma centers. The company's net income for the quarter was $39.1 million, a significant improvement from the net loss of $31.9 million reported in the same period last year. This increase was primarily due to a non-cash remeasurement of the contingent earnout liability associated with the company's August 2021 merger with Alpha Healthcare Acquisition Corp. Humacyte's cash, cash equivalents, and restricted cash as of March 31, 2025, were $113.2 million. The company also implemented cost reduction measures, including a workforce reduction of approximately 31 employees, to extend its cash runway and better align its organizational structure with its top business objectives. These measures are expected to result in net savings of approximately $13.8 million in 2025 and up to $38.0 million in 2026.